Show simple item record

dc.contributor.authorTrimboli, RM
dc.contributor.authorGiorgi Rossi, P
dc.contributor.authorBattisti, NML
dc.contributor.authorCozzi, A
dc.contributor.authorMagni, V
dc.contributor.authorZanardo, M
dc.contributor.authorSardanelli, F
dc.date.accessioned2020-10-21T08:42:41Z
dc.date.issued2020-09-25
dc.identifier.citationInsights into imaging, 2020, 11 (1), pp. 105 - ?
dc.identifier.issn1869-4101
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4179
dc.identifier.eissn1869-4101
dc.identifier.doi10.1186/s13244-020-00905-3
dc.description.abstractBreast cancer (BC) is the most common female cancer and the second cause of death among women worldwide. The 5-year relative survival rate recently improved up to 90% due to increased population coverage and women's attendance to organised mammography screening as well as to advances in therapies, especially systemic treatments. Screening attendance is associated with a mortality reduction of at least 30% and a 40% lower risk of advanced disease. The stage at diagnosis remains the strongest predictor of recurrences. Systemic treatments evolved dramatically over the last 20 years: aromatase inhibitors improved the treatment of early-stage luminal BC; targeted monoclonal antibodies changed the natural history of anti-human epidermal growth factor receptor 2-positive (HER2) disease; immunotherapy is currently investigated in patients with triple-negative BC; gene expression profiling is now used with the aim of personalising systemic treatments. In the era of precision medicine, it is a challenging task to define the relative contribution of early diagnosis by screening mammography and systemic treatments in determining BC survival. Estimated contributions before 2000 were 46% for screening and 54% for treatment advances and after 2000, 37% and 63%, respectively. A model showed that the 10-year recurrence rate would be 30% and 25% using respectively chemotherapy or novel treatments in the absence of screening, but would drop to 19% and 15% respectively if associated with mammography screening. Early detection per se has not a curative intent and systemic treatment has limited benefit on advanced stages. Both screening mammography and systemic therapies continue to positively contribute to BC prognosis.
dc.formatElectronic
dc.format.extent105 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleDo we still need breast cancer screening in the era of targeted therapies and precision medicine?
dc.typeJournal Article
dcterms.dateAccepted2020-08-20
rioxxterms.versionofrecord10.1186/s13244-020-00905-3
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2020-09-25
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfInsights into imaging
pubs.issue1
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Breast Cancer Clinical Research
pubs.publication-statusPublished
pubs.volume11
pubs.embargo.termsNo embargo
icr.researchteamBreast Cancer Clinical Researchen_US
dc.contributor.icrauthorBattisti, Nicoloen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0